Edition:
India

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

55.83USD
15 Dec 2017
Change (% chg)

$1.88 (+3.48%)
Prev Close
$53.95
Open
$54.00
Day's High
$55.85
Day's Low
$54.00
Volume
252,573
Avg. Vol
79,708
52-wk High
$55.85
52-wk Low
$25.92

Chart for

About

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets:... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $927.79
Shares Outstanding(Mil.): 19.09
Dividend: --
Yield (%): --

Financials

BRIEF-Enanta Pharma Says Abbvie’s Maviret ‍is Now Commercially Available In Japan​

* ENANTA PHARMACEUTICALS - ABBVIE'S MAVIRET HAS BEEN APPROVED FOR REIMBURSEMENT BY MINISTRY OF HEALTH, LABOUR AND WELFARE

30 Nov 2017

BRIEF-Enanta Pharma Q4 earnings per share $1.86

* Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017

21 Nov 2017

BRIEF-Enanta Pharmaceuticals reports positive phase 1 A/B clinical results for its lead fxr agonist

* Enanta Pharmaceuticals announces positive phase 1 a/b clinical results for its lead fxr agonist, edp-305

23 Oct 2017

BRIEF-Enanta Pharmaceuticals announces new data presentations on EDP-305

* Enanta Pharmaceuticals announces new data presentations on EDP-305, an FXR agonist for NASH and PBC, at The Liver Meeting 2017

28 Sep 2017

BRIEF-Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c

* Enanta announces that Abbvie’s Maviret (glecaprevir/pibrentasvir) received approval in Japan for the treatment of all major genotypes (GT1-6) of chronic hepatitis c

27 Sep 2017

BRIEF-Enanta Pharmaceuticals announces the appointment of Kristine Peterson to its board of directors

* Enanta Pharmaceuticals announces the appointment of Kristine Peterson to its board of directors

13 Sep 2017

BRIEF-Enanta pharmaceuticals Q3 loss per share $0.44

* Enanta pharmaceuticals reports financial results for its fiscal third quarter ended june 30, 2017

08 Aug 2017

BRIEF-Enanta Pharmaceuticals announces new data on EDP-938

* Phase 1 clinical study for RSV expected to begin in fourth calendar quarter of 2017

26 Jun 2017

BRIEF-Enanta announces that AbbVie receives CHMP positive opinion for MAVIRET

* Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6)

23 Jun 2017

Earnings vs. Estimates